🇺🇸 FDA
Patent

US 12398379

Compositions and methods for treating ornithine transcarbamylase deficiency

granted A61KA61K48/00A61P

Quick answer

US patent 12398379 (Compositions and methods for treating ornithine transcarbamylase deficiency) held by ARCTURUS THERAPEUTICS, INC. expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARCTURUS THERAPEUTICS, INC.
Grant date
Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K48/00, A61P, A61P9/00